Research programme: herpes simplex virus type 2 vaccines - Genocea BiosciencesAlternative Names: GEN-002; HSV-2 prophylactic (Px) vaccine - Genocea Biosciences; HSV-2 Px; ICP4383-766 + gD2; ICP4383-766 + TMR341-363; ICP4383-766 and gD2
Latest Information Update: 20 Nov 2015
At a glance
- Originator Fred Hutchinson Cancer Research Center; Genocea Biosciences; University of Washington
- Developer Genocea Biosciences
- Class Viral vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Herpes simplex virus type 2 infections